- Home
- GLPG vs HLMN Comparison
GLPG vs HLMN Comparison
Compare GLPG & HLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- HLMN
- Stock Information
- Founded
- GLPG 1999
- HLMN 1964
- Country
- GLPG Belgium
- HLMN United States
- Employees
- GLPG N/A
- HLMN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- HLMN Industrial Machinery/Components
- Sector
- GLPG Health Care
- HLMN Consumer Discretionary
- Exchange
- GLPG Nasdaq
- HLMN Nasdaq
- Market Cap
- GLPG 2.1B
- HLMN 1.9B
- IPO Year
- GLPG 2005
- HLMN N/A
- Fundamental
- Price
- GLPG $30.42
- HLMN $8.00
- Analyst Decision
- GLPG Hold
- HLMN Buy
- Analyst Count
- GLPG 4
- HLMN 6
- Target Price
- GLPG $31.33
- HLMN $12.20
- AVG Volume (30 Days)
- GLPG 169.3K
- HLMN 1.0M
- Earning Date
- GLPG 11-05-2025
- HLMN 11-04-2025
- Dividend Yield
- GLPG N/A
- HLMN N/A
- EPS Growth
- GLPG N/A
- HLMN 388.43
- EPS
- GLPG N/A
- HLMN 0.19
- Revenue
- GLPG $336,643,201.00
- HLMN $1,536,647,000.00
- Revenue This Year
- GLPG $1.77
- HLMN $8.11
- Revenue Next Year
- GLPG $0.44
- HLMN $7.85
- P/E Ratio
- GLPG N/A
- HLMN $42.17
- Revenue Growth
- GLPG 10.31
- HLMN 4.47
- 52 Week Low
- GLPG $22.36
- HLMN $6.55
- 52 Week High
- GLPG $37.78
- HLMN $11.64
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- HLMN 22.75
- Support Level
- GLPG $30.17
- HLMN $8.56
- Resistance Level
- GLPG $33.12
- HLMN $8.93
- Average True Range (ATR)
- GLPG 0.75
- HLMN 0.29
- MACD
- GLPG -0.04
- HLMN -0.10
- Stochastic Oscillator
- GLPG 22.55
- HLMN 5.76
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About HLMN Hillman Solutions Corp.
Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the company are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the U.S., Canada and Mexico.